<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017199</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068660</org_study_id>
    <secondary_id>OSU-00H0328</secondary_id>
    <secondary_id>NCI-1856</secondary_id>
    <nct_id>NCT00017199</nct_id>
  </id_info>
  <brief_title>PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have&#xD;
      metastatic neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate of patients with metastatic neuroendocrine tumors&#xD;
           treated with bortezomib.&#xD;
&#xD;
        -  Determine the toxicity of this drug in this patient population.&#xD;
&#xD;
        -  Determine the pharmacodynamics to correlate proteasome inhibition and efficacy of this&#xD;
           drug in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats&#xD;
      every 21 days for at least 8 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-25 patients will be accrued for this study within 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Islet Cell Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic carcinoid tumor or islet cell tumor&#xD;
&#xD;
               -  Well-differentiated neuroendocrine tumor OR&#xD;
&#xD;
               -  Well-differentiated neuroendocrine carcinoma&#xD;
&#xD;
          -  Measurable disease in at least 1 dimension&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are considered nonmeasurable:&#xD;
&#xD;
                    -  Lesions in a previously irradiated area&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Leukocyte count at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No ongoing active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study&#xD;
&#xD;
          -  No history of allergic reaction to compounds of similar chemical or biologic&#xD;
             composition to bortezomib&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy (interferon alfa)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy regimen (except hepatic artery&#xD;
             chemoembolization)&#xD;
&#xD;
          -  At least 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 12 weeks since prior hepatic artery chemoembolization (unless liver lesions&#xD;
             are not indicator lesions)&#xD;
&#xD;
          -  Stable dose long-acting octreotide therapy (Sandostatin LAR) within the past 3 months&#xD;
             allowed&#xD;
&#xD;
          -  Concurrent subcutaneous octreotide for breakthrough symptomatic relief allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents, commercial agents, or therapies&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha H. Shah, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>insulinoma</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>glucagonoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

